Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
9.2
4.8
Journals
Biomolecules
Special Issues
New Insights into Mechanisms and Therapeutics for Cardiovascular Disorders: 2nd...
share announcement

New Insights into Mechanisms and Therapeutics for Cardiovascular Disorders: 2nd Edition

A special issue of Biomolecules (ISSN 2218-273X). This special issue belongs to the section "Molecular Medicine".

Deadline for manuscript submissions: 31 August 2026 | Viewed by 7918

Special Issue Editors

Prof. Dr. Carola Yvette Förster

E-Mail Website
Guest Editor
Department of Anesthesiology, Intensive Care, Emergency and Pain Medicine, Section Cerebrovascular Sciences and Neuromodulation, University Hospital Würzburg, 97080 Würzburg, Germany
Interests: cerebrovascular biology; cardiovascular biology; brain-heart; brain cancer; neuroinflammation; ischemic brain injury; systems biology and mathematical modeling
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Mohsin Saleet Jafri

E-Mail Website
Guest Editor
School of Systems Biology and the Krasnow Institute for Advanced Study, George Mason University, Fairfax, VA 22030, USA
Interests: multiscale systems biology; computational biology; bioinformatics; cardiac physiology; immunology; mitochondria; cellular signaling; neuroscience; algorithms; HPC
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Tarun W. Dasari

E-Mail Website
Guest Editor
University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
Interests: cardiovascular diseases
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Following a very successful first run, we are pleased to announce the launch of a second edition of a Special Issue on New Insights into Mechanisms and Therapeutics for Cardiovascular Disorders.

Cardiovascular disease is the leading cause of death worldwide.  Cardiovascular disease includes heart failure, ischemia, deep vein thrombosis, pulmonary embolism, heart valve disease, pericarditis, rheumatic heart disease, stroke, and other disorders.  Understanding the molecular and physiological mechanisms is necessary for developing effective therapeutics.  This requires both experimental and computational research modalities, spanning scales from the molecular to the organ system level.  Hence, insights can be gained through detailed studies at a particular scale and integrative studies that span multiple scales.  Advances in the treatment of cardiovascular disease require research that spans from basic science to translational research and, ultimately, to clinical studies.  This is reflected in recent advances in molecular biomarkers, which provide both mechanistic insights and clinically actionable treatment strategies.

This Special Issue of Biomolecules will highlight new insights into the mechanisms and therapeutics developed to manage cardiovascular disease. Both new research papers and reviews describing the state of the field and important new directions are welcome.

Prof. Dr. Carola Yvette Förster
Prof. Dr. Mohsin Saleet Jafri
Prof. Dr. Tarun W. Dasari
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • brain–heart axis
  • heart and stroke
  • stress-induced cardiomyopathy
  • cardiovascular disease

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Related Special Issue

Published Papers (3 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

18 pages, 739 KB  
Review
Metabolic Drivers of Valve Calcification and Atrial Remodeling in Calcific Aortic Stenosis
by Simina Mariana Moroz, Alina Gabriela Negru, Silvia Luca, Mihaela Valcovici, Mirela Baba, Alina Maria Lupu, Ana Lascu, Daniel Florin Lighezan and Ioana Mozos
Biomolecules 2026, 16(2), 251; https://doi.org/10.3390/biom16020251 - 4 Feb 2026
Cited by 1 | Viewed by 839
Abstract
AS, one of the most common forms of valvular heart disease, requiring intervention in aging populations in Europe and North America, has traditionally been viewed as a passive, degenerative condition. However, growing evidence supports a paradigm shift toward recognizing AS as an active [...] Read more.
AS, one of the most common forms of valvular heart disease, requiring intervention in aging populations in Europe and North America, has traditionally been viewed as a passive, degenerative condition. However, growing evidence supports a paradigm shift toward recognizing AS as an active metabolic and inflammatory disorder. This narrative review synthesizes experimental, translational, and clinical evidence published between 2015 and 2025 examining metabolic mechanisms linking valvular calcification and atrial remodeling in AS and discusses their clinical relevance in the context of transcatheter aortic valve replacement (TAVR). We discussed classical pathways involving mineral metabolism and vitamin signaling, alongside emerging roles of lipid oxidation, mitochondrial dysfunction, epigenetic regulation, and gut microbiome-derived metabolites. Further, metabolomic signatures associated with disease severity and post-TAVR outcomes were reviewed, highlighting the predominantly associative nature and current limitations of these data. Although valve replacement remains the only effective therapy for advanced AS, metabolic and multi-omics insights may improve future risk stratification and mechanistic understanding. Metabolomic profiling could be integrated at multiple points in the clinical pathway for aortic stenosis and TAVR—most promisingly for pre-procedural risk stratification. The present paper focuses on an integrative framework in which valvular calcification and atrial remodeling are viewed within a broader context of metabolic dysregulation. Future research should aim to translate molecular biomarkers into real-world diagnostics and targeted interventions. Full article
(This article belongs to the Special Issue New Insights into Mechanisms and Therapeutics for Cardiovascular Disorders: 2nd Edition)
►▼ Show Figures

Figure 1

28 pages, 770 KB  
Review
Leveraging Artificial Intelligence and Modulation of Oxidative Stressors to Enhance Healthspan and Radical Longevity
by Donald D. Haines, Stephen Christopher Rose, Fred M. Cowan, Fadia F. Mahmoud, Albert A. Rizvanov and Arpad Tosaki
Biomolecules 2025, 15(11), 1501; https://doi.org/10.3390/biom15111501 - 24 Oct 2025
Cited by 4 | Viewed by 3112
Abstract
This review explores the transformative potentials of artificial intelligence (AI) in promoting healthspan and longevity. Healthspan focuses on enhancing quality of life free from chronic conditions, while longevity defines current lifespan limits within a particular species and encompasses biological aging at multiple levels. [...] Read more.
This review explores the transformative potentials of artificial intelligence (AI) in promoting healthspan and longevity. Healthspan focuses on enhancing quality of life free from chronic conditions, while longevity defines current lifespan limits within a particular species and encompasses biological aging at multiple levels. AI methodologies—including machine learning, deep learning, natural language processing, robotics, and data analytics—offer unprecedented tools to analyze complex biological data, accelerate biomarker discovery, optimize therapeutic interventions, and personalize medicine. Notably, AI has facilitated breakthroughs in identifying accurate biomarkers of biological age, developing precision medicine approaches, accelerating drug discovery, and enhancing genomic editing technologies such as CRISPR. Further, AI-based analysis of endogenous cytoprotection, especially the activity of molecules such as heme oxygenase, with particular application to hemolytic diseases. AI-driven robotics and automated monitoring systems significantly improve elderly care, lifestyle interventions, and clinical trials, demonstrating considerable potential to extend both healthspan and lifespan. However, the integration of AI into longevity research poses ethical and societal challenges, including concerns over privacy, equitable access, and broader implications of extended human lifespans. Strategic interdisciplinary collaboration, transparent AI methodologies, standardized data frameworks, and equitable policy approaches are essential to responsibly harness AI’s full potential in transforming longevity science and improving human health. Full article
(This article belongs to the Special Issue New Insights into Mechanisms and Therapeutics for Cardiovascular Disorders: 2nd Edition)
►▼ Show Figures

Figure 1

21 pages, 487 KB  
Review
Role of Glucagon-like Peptide-1 Receptor Agonists (GLP-1RAs) in Patients with Chronic Heart Failure
by Pasqual Llongueras-Espí, Elena García-Romero, Josep Comín-Colet and José González-Costello
Biomolecules 2025, 15(9), 1342; https://doi.org/10.3390/biom15091342 - 19 Sep 2025
Cited by 2 | Viewed by 3502
Abstract
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used in the management of type 2 diabetes and obesity due to their metabolic benefits. Beyond weight loss and glycemic control, emerging evidence suggests they may also exert cardioprotective effects. In the context of heart failure [...] Read more.
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used in the management of type 2 diabetes and obesity due to their metabolic benefits. Beyond weight loss and glycemic control, emerging evidence suggests they may also exert cardioprotective effects. In the context of heart failure (HF), particularly HF with preserved ejection fraction (HFpEF), GLP-1RAs have been associated with improvement in symptoms, physical capacity, biomarkers, and structural cardiac remodeling. These benefits appear to be independent of weight loss, suggesting additional mechanisms including anti-inflammatory effects, improved myocardial metabolism or modulation of epicardial adipose tissue. However, current data largely come from non-HF dedicated trials, with limited standardization of the HF phenotype. Results are overall inconsistent and may suggest potential harm in some cases, particularly in HF with reduced ejection fraction (HFrEF). This review aims to summarize the current evidence on the role of GLP-1RAs in heart failure, explore possible underlying mechanisms and highlight key gaps in knowledge. Full article
(This article belongs to the Special Issue New Insights into Mechanisms and Therapeutics for Cardiovascular Disorders: 2nd Edition)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-3
Back to TopTop